return equiti ttm
upgrad share outperform market perform rais
fair valu estim share base follow
head see execut commerci front
balanc drive near-term profit growth realiz long-term appreci
rational ad royalti olumi atop dermat peak sale estim
billion probabl model ad itacitinib acut chronic steroid-
nave gvhd graft versu host diseas peak sale estim billion probabl
model ad pemigatinib cholangiocarcinoma bladder cancer peak sale
million probabl model ad royalti capmatinib
nonsmall-cel lung cancer nsclc peak sale million probabl
model continu peak project revenu billion jakafi count
potenti life cycl manag product view remain prime
candid probability-adjust net present valu npv model assign per
share jakafi per share iclusig per share olumi pemigatinib
itacitinib also assign per share capmatinib royalti novarti ad
per share net cash year-end reach fair valu assess incyt
share exhibit
resurg pipelin believ two year disappoint stock
perform due epacadostat failur olumi baricitinib debacl
regulatori process rest pipelin final reach inflect point
also believ ideal candid larg pharma look blockbust
move needl ep accret healthi innov pipelin failur
studi epacadostat earli share experienc strong
neg sentiment exacerb olumi approv lower
dose mg treatment rheumatoid arthriti ra unit state howev
believ stock reach turn point plethora catalyst
prime acquisit target blockbust jakafi franchis matur
innov pipelin regulatori catalyst includ approv jakafi steroid-
refractori acut gvhd nda submiss pemigatinib refractori cholangiocarcinoma
nda submiss capmatinib nsclc partner novarti nv
entitl mileston royalti pivot data catalyst
includ jakafi itacitinib variou gvhd phase studi phase data
baricitinib atop dermat partner pemigatinib pivot
data bladder cancer follow nda file base proxim launch
success earlier stage data readout ad pemigatinib itacitinib olumi
atop dermat capmatinib model believ consist profit
pipelin success next month could start drive valu share
recov epacadostat franchis setback bar macro market trend
base wilmington delawar major oncology-focus biotechnolog compani
pipelin final come epacadostat shadow prospect also
strong upgrad outperform
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
project blockbust jakafi maintain double-digit year-over-year growth year come continu
forecast billion peak sale jakafi higher billion compani guidanc believ
jakafi doubl combo could extend franchis significantli date jakafi penetr elig
myelofibrosi mf popul polycythemia vera pv popul unit state ampl room
growth opinion peak estim jakafi penetr elig mf popul
elig pv popul jakafi remain approv therapi indic potenti
competitor near medium term also third quarter fda accept supplement new drug
applic snda jakafi steroid-refractori acut gvhd current model contribut million
peak sale jakafi also evalu steroid-refractori chronic gvhd essenti thrombocytopenia et
compani continu explor combin in-hous agent includ pim inhibitor itacitinib
inhibitor inhibitor life cycl manag npv analysi jakafi franchis ascrib
olumi phase atop dermat data expect earli olumi jak inhibitor partner
approv fda first indic treatment moder sever ra june olumi second
indic moder sever atop dermat patient refractori topic steroid expect releas data
phase studi earli expect file nda follow potenti approv post-top
moder sever atop dermat unit state europ respect conserv
estim six-month treatment durat due variou competit treatment option look potenti increas
treatment durat base phase trial result ascrib probabl commerci olumi
atop dermat exhibit combin indic estim peak sale approxim billion billion
ra billion atop dermat stand receiv tier royalti rang
result peak revenu million npv analysi olumi royalti mileston stream come
valuat per share exhibit
drugstag developmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuejakafimarketedapprov nov eumarketedapprov juli eu februari tier tier year-end present valu addit fair valu william blair estimatesexhibit corporationfair valu william blair
look expand footprint beyond jakafi steroid-refractori gvhd gravita program select
inhibitor itacitinib cover unmet need steroid-nav prophylact gvhd space
itacitinib pace potenti approv extend beyond jakafi breadth treatment steroid-refractori
acut chronic gvhd compani use itacitinib target steroid-nav acut chronic gvhd first phase trial
itacitinib seek enrol patient steroid-nav acut gvhd random receiv
itacitinib placebo combin steroid primari endpoint orr overal respons rate day top-lin
data expect success would lead itacitinib first global regulatori submiss second phase
studi steroid-nav chronic gvhd expect initi first half success manag
project itacitinib see approv second indic time frame itacitinib also enter
evalu potenti prophylact treatment phase studi estim top-lin data
studi avail second half model potenti launch itacitinib unit state
europ respect ascrib probabl success estim averag treatment durat month
acut gvhd month chronic gvhd estim treatment cost per year project popul
roughli combin acut chronic steroid-na gvhd patient estim peak market penetr
peak sale billion indic current ascrib per share itacitinib franchis
exhibit tabl competit agent develop gvhd view exhibit
drug candidateindicationpopul addressedu incid target populationprob successlaunch datewb modelpeak shareprice/yeartreat durationpeak salespeak global salesvaluationolumiantatop dermatitismoder sever atop dermat patient gvhdsteroid-na acut chronic month month diagnos metastat unresect patient cancernewli diagnos metastat unresect patient mutat advanc non-smal cell lung william blair estim compani reportssourc william blair estim compani reportsexhibit corporationmodel assumpt ad indicationscompani name origin product nametargetstherapeut modalitydevelop phasepartnersneovii grafalonantibodymarketedabbvi imbruvicabtksmal moleculemarketedjohnson johnsonmesoblast temcel hs stem cellmarketedjcr incyt moleculeregistrationnovarti kiadi pharma applicableimmun cellsphas iiiincyt itacitinib moleculephas iiiinnov biolog cytodyn iiielsali leukotac iiijazz oncoimmun proteinphas iijazz plcdefitelioctsgdna oligonucleotidesphas iikadmon hold moleculephas iimaat pharma iijohnson johnsonponesimod moleculephas iigeneron shanghai corp ltd promenakin proteinphas iifat inc protmunenot applicableprogram stem immun cellsphas iibiocon i/iiequilliumcellect ltd apograftstem cellphas i/iibellicum inc rivo-celnot availableimmun cellsphas i/iixeniko t-guardtcr proteinphas i/iitargazym i/iimerck co inc vorinostat msdhdacsmal moleculephas i/iisourc biocenturyexhibit corporationcompetit agent develop acut chronic gvhd william blair
base data two on-going studi inhibitor pemigatinib treatment
cholangiocarcinoma bladder cancer present european societi medic
oncolog esmo octob munich decid add pemigatinib model well believ
pemigatinib could first-in-class treatment second-lin cholangiocarcinoma transloc nda
file also believ pemigatinib could like player urotheli carcinoma uc bladder cancer
fusion continu dose pemigatinib set improv potenc expect given respons rate
jump seen johnson johnson compet agent erdafitinib compani plan initi two phase
studi cholangiocarcinoma uc first-lin treatment beyond two initi indic expect incyt
field move tumor fgfr aberr current ascrib per share pemigatinib franchis
exhibit summar inhibitor develop exhibit
interim result trial pois pemigatinib first-in-class select inhibitor
patient advanced/ metastat surgic unresect cholangiocarcinoma studi
phase ii open-label multicent studi pemigatinib select fgfr inhibitor patient
advanced/metastat surgic unresect cholangiocarcinoma known fgfr altern fail
least one prior line treatment patient enrol three cohort patient known
transloc patient fgf/fgfr alter patient fgf/fgfr alter note
cholangiocarcinoma often diagnos late stage stage iv prognosi poor
transloc preval intrahepat cholangiocarcinoma annual incid
patient unit state eu japan interim data demonstr orr
month patient transloc patient fgf/fgfr alter
candidatecompanytargetind stage developmentnsclcapprovedsarcomaphas iiivari cancer colorect gastric thyroid liver renal sclcphase ii/iiibladd cancerregistrationbiliari cancer esophag cancer gastric cancer nsclcphase iiderazantinib arq inc small cancerphas iiiren cancerphas iiibreast cancer solid tumorsphas plcsmall cancer nsclc solid tumorsphas iiinfigratinib therapeuticssmal cancerphas iisulfatinib china meditech ltd small tumorsphas iiipemigatinib corp small cancer bladder cancer cholangiocarcinoma liquid tumorsphas lilli co small unspecifi phase oncologysmal tumorsphas sankyo co ltd small cord injuri strokephas iivofatamab therapeuticsmonoclon cancerphas pharma inc small tumorsphas irogaratinib agsmal cancer solid tumorsphas biopharma inc small tumorsphas medicinesmal cancerphas biocenturyexhibit corporationselect fgfr inhibitor developmentanlotinib laboratori llcsmall lactat johnsonsmal william blair
fgf/fgfr alter orr patient respect pemigatinib well-toler
common grade greater teae includ hypophosphatemia hyponatremia abdomin pain
arthralgia patient teae fatal outcom none relat studi treatment
closest competitor qed privat infigratinib produc orr month
set date slightli shorter follow-up pend releas full data set incyt
anticip submit nda fda first-in-class fgfr treatment indic
enrol patient phase open-label studi administ frontlin metastat unresect
cholangiocarcinoma patient continu dose schedul pemigatinib compar gemcitabine-
continu dose pemigatinib urotheli carcinoma phase ii trial like reveal
competit respons rate patient mutat transloc trial open-
label multicent phase ii studi patient metastat surgic unresect uc muc trial two
patient popul patient mutat fusion patient fgf/fgfr alter
transloc preval roughli newli diagnos uc patient unit state eu
japan annual incid patient interim data phase ii trial
patient dose intermitt schedul oral pemigatinib mg qd cycl two week one week
produc overal respons rate orr patient mutat fusion
manag discontinu due trae treatment relat death result similar
johnson johnson intermitt dose compet pan-fgfr inhibitor erdafitinib mg qd cycl
one week one week achiev orr across fgfr alter johnson johnson howev
also demonstr higher orr use continu dose schedul erdafitinib mg respons
updat includ continu dose arm pemigatinib mg qd data expect
read consid pemigatinib similar mechan fgfr inhibit demonstr superior
pharmacodynam preclin model believ continu dose schedul pemigatinib produc
competit orr compar johnson johnson erdafitinib safeti profil continu dose also
close watch evalu note continu dose regimen taken forward
phase studi frontlin cholangiocarcinoma bladder cancer
fgfr altern preval number cancer includ model provid upsid
estim asid cholangiocarcinoma bladder cancer activ run pemigatinib clinic trial
target ultra-rar form myeloprolif syndrom contain transloc
affect patient year current approv therapi aggress diseas also
plan initi tumor-agnost pivot trail sever cancer type fgfr mutat
fusion includ endometri carcinoma glioblastoma squamou nonsmall-cel lung
cancer rectal cancer head neck squamou cell carcinoma scc well solid
tumor greater patient fgfr mutat fusion across indic
greater potenti addit patient per year unit state eu japan yet
includ model
across bladder cancer cholangiocarcinoma estim million global peak sale pemigatinib
valu franchis per share expect compani submit nda pemigatinib second-lin
cholangiocarcinoma transloc drug candid enter market
probabl success pemigatinib bladder cancer target diagnos metastat unresect
patient transloc mutat anticip compani read data phase ii studi
bladder cancer use continu dose follow potenti approv launch unit
state europ respect assign probabl success expect pemigatinib approv
frontlin set two tumor type time frame conserv model averag blend
treatment durat month second-lin frontlin cholangiocarcinoma base median
achiev second-lin cholangiocarcinoma anticip increas frontlin
patient alreadi achiev median month standard care treatment also project six-month
treatment durat bladder cancer overal estim peak penetr pemigatinib
cholangiocarcinoma bladder cancer de novo relaps metastat cancer respect leav room
potenti competit project million peak sale cholangiocarcinoma million
peak sale bladder cancer combin indic estim roughli million global peak sale
beyond candid believ select number earlier-stag candid start move
forefront could add valu near medium term addit program includ topic jakafi
treatment vitiligo deep pipelin oncolog candid includ oral inhibitor first bispecif
antibodi meru collabor hold high promis view
beyond oncolog data true-derm program topic jakafi treatment vitiligo expect
data phase iib studi topic jakafi treat atop dermat present european
academi dermatolog venerolog eadv annual congress septemb pari ruxolitinib cream
treatment result prompt improv easi iga pruritus/itch associ safeti toler
find regulatori discuss alreadi underway regard phase design await potenti phase
studi initi
proof-of-concept data citadel program inhibitor candid parsaclisib
anticip read treatment relapsed/refractori r/r set follicular
lymphoma fl margin zone lymphoma mzl mantl cell lymphoma mcl late
compani expect proof-of-concept data three monotherapi trial
fl mzl mcl respect success studi enabl seek acceler
approv support initi phase program versu standard care indic also
conduct parasaclisib clinic proof-of-concept trial three autoimmun indic pemphigu vulgari
autoimmun hemolyt anemia sjgren syndrom
compani develop program evalu inhibitor candid
treatment variou malign data expect read
compani seek rapid approv candid select tumor type compani push
develop three initi indic msi-high microsatellit instability-high endometri cancer merkel
cell carcinoma data expect anal cancer data expect compani also
explor synergi multipl larg small molecul intern product candid combin therapi
also initi first-in-human studi oral small molecul inhibitor
end phase trial patient confirm advanc solid tumor measur lesion
fail least one prior treatment preclin test profil similar
monoclon antibodi treatment howev uniqu mechan action intern cancer
immun cell result function inhibit signal also advantag oral
administr includ potenti all-or combin treatment futur
collabor meru mru also develop portfolio novel bispecif antibodi
treatment variou cancer first one enter clinic second quarter
meru announc global collabor develop bispecif antibodi use meruss biclon platform
grant exclus right bispecif antibodi program contrast standard antibodi
bind singl target bispecif antibodi bind two distinct target enabl vast array new treatment
strategi fda recent accept ind first pipelin candid variou solid tumor
clinic trial expect begin second quarter uniqu immunostimulatori profil mcla-
bind activ immun cell simultan bind block inhibitori immun signal
mani cancer produc
upcom catalyst includ approv jakafi steroid-refractori acut gvhd nda
submiss pemigatinib cholangiocarcinoma phase data jakafi steroid-refractori acut chronic gvhd
phase ii data ruxolitinib cream vitiligo phase data itacitinib steroid-nav acut gvhd
proof concept data margin zone lymphoma mzl mantl cell lymphoma mcl follicular
lymphoma fl
risk outperform rate includ clinic risk pipelin unforeseen competit
jakafi safeti risk olumi
